A phase 2/3 trial of an investigational treatment in prostate cancer, run by Five Eleven Pharma, Inc., now recruiting.
PSMA-PET to Guide Prostatectomy is a phase 2/3 interventional study registered as NCT05381103 by Five Eleven Pharma, Inc., with 288 participants planned, started 2021-10-01 and due to reach its primary completion in 2028-06-01.
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
Shares PSMA, Prostate cancer and the tag pipeline.
Shares PSMA, Prostate cancer and the tag pipeline.
Shares PSMA, Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), PSMA, Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography), Prostate cancer and the tag pipeline.
Shares PET (positron emission tomography) and the tag pipeline.